$298 Million

Avidity Biosciences

Initial Public Offering

Lead Left Bookrunner, June 2020

Avidity Biosciences

Avidity Biosciences, Inc. (“Avidity” or “the Company”) is an early-stage biotech company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. The company utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity is initially focused on muscle tissue to demonstrate the capabilities of its AOCs, and its muscle franchise consists of five programs. The lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1 (DM1), a rare monogenic muscle disease.